Curaleaf Enhances Offer to Acquire Aurora Cannabis
The enhanced proposal raises the cash component by 33% and would issue 0.4013 Curaleaf shares for each Aurora share acquired.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Curaleaf (CURLF) plans to enhance its offer to acquire all outstanding Aurora Cannabis common shares to US$5.00 per share in implied consideration. The proposed terms comprise 0.4013 Curaleaf shares plus US$1.00 cash per Aurora share, based on Curaleaf's October 2, 2026 closing share price and the stated exchange rate. Total implied consideration rises 25%, cash consideration rises 33%, and the maximum consideration increases 20% to US$6.00 per Aurora share.
Curaleaf expects to extend the offer deadline to 11:59pm Mountain Time on December 4, 2026. The proposal was developed solely from public information, with formal due diligence still sought. The proposed combination would have more than US$1.5 billion in last-twelve-month revenue, nearly US$350 million in adjusted EBITDA, an earnings measure, and at least US$40 million in expected annual cost savings.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Expected annual cost savings from the proposed combination total at least US$40 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed combined business would have more than US$1.5 billion in last-twelve-month revenue.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed combined business would have nearly US$350 million in last-twelve-month adjusted EBITDA.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed combination would span 17 countries, with pro forma market capitalization exceeding US$3 billion.
Negative
- Moderate pointTotal implied acquisition consideration increases 25% to US$5.00 per Aurora share.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed issuance of 0.4013 Curaleaf shares per Aurora share would dilute existing Curaleaf holders.
- Minor pointCash acquisition consideration increases 33% to US$1.00 per Aurora share, approximately 20% of the consideration mix.
- Minor pointMaximum acquisition consideration increases 20% to US$6.00 per Aurora share.
- Minor pointEnhanced proposal relies solely on public information; Curaleaf still seeks formal due diligence.
News Explained
Under the proposed terms, Curaleaf would issue 0.4013 shares for each Aurora share acquired, giving Aurora holders Curaleaf equity; issuing those shares would increase Curaleaf’s share count and reduce existing holders’ percentage ownership if the offer is completed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Increases total implied consideration by
Increases Cash consideration by
Increases Share Consideration to 0.4013 Curaleaf shares per Aurora Share and increases the Cap Price by
Enhanced proposal developed solely from publicly available information; Curaleaf remains committed to engaging with Aurora in a formal due diligence process and urges Aurora's Board to engage in good faith discussions regarding the Enhanced Offer
Enhanced Offer continues to provide Aurora Shareholders with the opportunity to become owners of the premium global cannabis platform and participate in the significant long-term upside of the combined company
Under the terms of the Enhanced Offer, Aurora shareholders would receive total implied consideration of
The Enhanced Offer will also increase the Offer's maximum consideration per Aurora Share from
Boris Jordan, Chairman of the Board and Chief Executive Officer of Curaleaf, stated:
"Over the past several weeks, we have met with a significant percentage of Aurora's shareholder base, all of whom are supportive of the strategic rationale for the deal. This increased offer reflects careful consideration and shareholder input, demonstrating our continued commitment to reaching a successful outcome.
"Importantly, we are enhancing our proposal despite Aurora's refusal to engage and provide access to customary due diligence. We view this as a significant good-faith step that demonstrates our conviction in the merits of a combination and the value creation opportunity it represents.
"We have demonstrated our willingness to act in the best interest of shareholders. While this is not how we would expect to engage in a sale process, we are prepared to act because we believe strongly in the value creation opportunity. Importantly, if Aurora is providing diligence access to other parties, shareholders deserve a fair and open process that includes Curaleaf."
A combination of Curaleaf and Aurora would create the global cannabis leader, with operations across 17 countries, more than
The combined company would be a larger, more diversified global cannabis platform with a pro forma market capitalization in excess of
Curaleaf will be filing a Notice of Variation, Change and Extension (the "Notice of Variation and Change") to its Offer to Purchase and Circular and related offer materials to reflect the Enhanced Offer with the applicable Canadian securities regulatory authorities and a new Registration Statement on Form F-80 with the
Although we do not believe required, as a sign of our commitment to the Enhanced Offer, the Notice of Variation and Change will also include the pro forma financial statements that Aurora suggests should be provided. The Notice of Variation and Change will also extend the Expiry Time under the Offer from 5:00pm (Mountain Time) on December 1, 2026 to 11:59pm (Mountain Time) on December 4, 2026.
IMPORTANT INFORMATION
This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The Offer by Curaleaf to purchase all outstanding common shares of Aurora is made solely by the Offer to Purchase and Circular dated August 18, 2026, as amended by the Notice of Variation and Change and as may be further amended or supplemented.
SECURITY HOLDERS ARE URGED TO READ THE NOTICE OF VARIATION AND CHANGE AS WELL AS THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENTS ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Free copies are available at www.sedarplus.ca, www.sec.gov or by contacting the Information Agent, Carson Proxy Advisors, at 1-800-530-5189 (toll-free), 416-751-2066 (local/text), or info@carsonproxy.com.
NOTICE TO
The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country.
Investors should be aware that the bidder or its affiliates, directly or indirectly, may bid for or make purchases of the issuer's securities subject to the offer or of the issuer's related securities, or of the bidder's securities to be distributed or of the bidder's related securities, during the period of the tender offer, as permitted by applicable Canadian laws or provincial laws or regulations.
Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the
THE OFFER AND THE OFFEROR SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY
The Curaleaf Shares to be issued under the Offer have not been registered or otherwise qualified for offer and sale in certain
FORWARD-LOOKING INFORMATION
This document contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of applicable U.S. securities laws. Such statements relate to, among other things, the expected benefits, timing, and effects of the Offer, the timing for filing of the Notice of Variation and Change, and anticipated synergies from a combination of Curaleaf and Aurora. Forward-looking statements can often be identified by words such as "believes," "expects," "anticipates," "may," "will," or similar expressions.
Actual results may differ materially due to risks including: changes in general economic conditions; failure to satisfy conditions to the Offer; failure to realize anticipated synergies; fluctuations in foreign exchange and interest rates; regulatory changes; and other risks described under "Risk Factors" in the Offer to Purchase and Circular. The safe harbor for forward-looking statements does not apply to statements made in connection with a tender offer. Security holders should not place undue reliance on forward-looking information. Curaleaf disclaims any obligation to update forward-looking information except as required by law.
AURORA INFORMATION
Information concerning Aurora herein is based solely on Aurora's publicly available filings and other public sources. Aurora has not reviewed this document. Neither Curaleaf nor its officers or directors assumes responsibility for the accuracy or completeness of such information.
ADDITIONAL INFORMATION
The disposition of Common Shares and the acquisition of Curaleaf shares may have U.S. and Canadian tax consequences; shareholders should consult their own tax advisors and review the tax disclosure contained in the Offer to Purchase and Circular which are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Contacts
Media Contact
Kekst CNC
Kekst-Curaleaf@kekstcnc.com
Investor Contact
Curaleaf Holdings, Inc.
IR@curaleaf.com
Shareholder Contact
Carson Proxy Advisors
North American Toll Free Phone: 1-800-530-5189
Local (Collect outside North America): 416-751-2066
Email: info@carsonproxy.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/curaleaf-enhances-offer-to-acquire-aurora-cannabis-302898362.html
SOURCE Curaleaf Holdings, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Curaleaf's enhanced offer for Aurora Cannabis?
Aurora shareholders would receive 0.4013 Curaleaf shares plus US$1.00 cash per Aurora share, implying US$5.00 in total consideration. That value uses Curaleaf's October 2, 2026 closing price of C$14.21 and an exchange rate of C$1.00 = US$0.7015. The proposed maximum consideration is US$6.00 per Aurora share.
When would Curaleaf's enhanced Aurora Cannabis offer expire?
Curaleaf plans to extend the offer deadline to 11:59pm Mountain Time on December 4, 2026. The planned extension changes the existing deadline of 5:00pm Mountain Time on December 1, 2026.
Are there U.S. state restrictions on Curaleaf's offer for Aurora Cannabis?
In certain U.S. states where the Curaleaf shares have not been registered or otherwise qualified for sale, the offer is available only to qualifying Exempt Institutional Investors. Those investors are described in the Offer to Purchase and Circular.